Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma

11 Nov 2020

Abstract excerpt

BACKGROUND: Chemotherapy is the only systemic treatment approved for pancreatic ductal adenocarcinoma (PDAC), with a selection of regimens based on patients' performance status and expected efficacy. The establishment of a potent stratification associated with chemotherapeutic efficacy could potentially improve prognosis by tailoring treatments. PATIENTS AND METHODS: Concomitant chemosensitivity and genome-wide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Ferroptosis and cancer prognosis
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33188873
DOI: 10.1016/j.annonc.2020.10.601

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinomaPMID 33188873Read ↗

Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancerSemantic proximity Read ↗

Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-derived organoidsSemantic proximity Read ↗

A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patientsSemantic proximity Read ↗

Meta-analysis of 1,200 transcriptomic profiles identifies a prognostic model for pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenograftsSemantic proximity Read ↗

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentSemantic proximity Read ↗

Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.Semantic proximity Read ↗

Pancreatic cancer survival analysis defines a signature that predicts outcomeSemantic proximity Read ↗

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancerSemantic proximity Read ↗

Real-world data validation of the PurIST pancreatic ductal adenocarcinoma gene expression classifier and its prognostic implicationsSemantic proximity Read ↗

A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft ModelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.